Peptide · developed by Novo Nordisk
Zenagamtide is an investigational agent given as a subcutaneous once-weekly injection and also as a daily oral tablet taken in the fasted state, studied in overweight, obesity and type 2 diabetes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07931495 | Phase 3 | Diabetes Mellitus, Type 2 | Not yet recruiting | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diabetes Mellitus, Type 2ObesityOverweight
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →